HRS-1780: Safety and Efficacy in Chronic Kidney Disease Patients
Here’s a breakdown of the key information from the provided text, focusing on HRS-1780 and the role of pharmacists:
HRS-1780 – Key findings:
* Efficacy: HRS-1780 (at 10mg and 20mg dosages) demonstrated significant reductions in 24-hour urine protein compared to placebo:
* 10mg: -29.4% reduction (P = .0068)
* 20mg: -47.3% reduction (P <.0001)
* Safety:
* Treatment-emergent adverse events (AEs) occurred in approximately 65.9%, 64.4%, and 55.6% of patients in the 10mg, 20mg, and placebo groups, respectively.
* Hyperkalemia: A notable safety concern. Incidence was 4.5% with 10mg and 15.6% with 20mg.
Pharmacist’s Role:
Pharmacists are crucial for the safe and effective implementation of HRS-1780 (and other novel nonsteroidal MRAs) in patient care. Specifically, they can:
* Patient Selection & Dosing: Evaluate patient suitability based on:
* Renal function
* Albuminuria
* Potassium levels
* Concurrent use of renin-angiotensin system inhibitors
* Safety Monitoring:
* Monitor laboratory parameters (especially potassium)
* Identify potential drug-drug interactions
* Educate patients about signs of adverse events (like hyperkalemia)
* adherence & Education:
* Support patient adherence to therapy
* Counsel patients on the cardiovascular and renal benefits
* Collaboration: Work with nephrology and cardiology teams to optimize outcomes, particularly for patients with comorbid CKD and type 2 diabetes.
Overall Message:
The text highlights HRS-1780 as a promising new therapy for Chronic Kidney Disease (CKD) and emphasizes the vital role pharmacists play in ensuring its safe and effective use. As more therapies like HRS-1780 become available, pharmacist involvement will be increasingly vital.